General Announcement::ANDA approval for Propafenone Hydrochloride Extended-Release Capsules USP 225 mg, 325 mg, and 425 mg

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
11-Sep-2017 13:02:03
Status
New
Announcement Sub Title
ANDA approval for Propafenone Hydrochloride Extended-Release Capsules USP 225 mg, 325 mg, and 425 mg
Announcement Reference
SG170911OTHRKL40
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
11/09/2017 10:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals receives ANDA approval for Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Attachments

PR_11.09.2017.pdf
Total size =828K